The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Highlighting CAR T Cell Options for Relapsed/Refractory DLBCL

David Miklos, MD
Published Online:6:55 PM, Thu March 14, 2019


David Miklos, MD, associate professor of medicine at Stanford University, discusses his advice for community oncologists treating patients with diffuse large B-cell lymphoma (DLBCL).

Miklos says it is important to know that chimeric antigen receptor (CAR) T cells are effective and available for patients with relapsed/refractory DLBCL. 

These therapies are available both commercially for the relapsed/refractory third-line setting, as well as in 3 randomized trials for the second-line, Miklos says. It is important for community oncologists to refer patients to CAR T-cell centers for these patients as it can change their outcomes.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.